Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Research & Development: 2022-2025

Historic Research & Development for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$43.7 million.

  • Abivax's Research & Development fell 40.52% to -$43.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$116.2 million, marking a year-over-year decrease of 66.11%. This contributed to the annual value of $156.6 million for FY2024, which is 41.05% up from last year.
  • Per Abivax's latest filing, its Research & Development stood at -$43.7 million for Q2 2025, which was down 5.82% from -$41.3 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Research & Development ranged from a high of -$49.28 in Q4 2022 and a low of -$43.7 million during Q2 2025.
  • Moreover, its 3-year median value for Research & Development was -$35.0 million (2024), whereas its average is -$25.8 million.
  • Data for Abivax's Research & Development shows a maximum YoY crashed of 125.33% (in 2023) over the last 5 years.
  • Abivax's Research & Development (Quarterly) stood at -$49.28 in 2022, then slumped by 125.33% to -$111.04 in 2023, then crashed by 40.99% to -$156.55 in 2024, then plummeted by 40.52% to -$43.7 million in 2025.
  • Its last three reported values are -$43.7 million in Q2 2025, -$41.3 million for Q1 2025, and -$156.55 during Q4 2024.